The penny stock space attracts millions of investors on a daily basis who are on the lookout for the next breakout star in the category. Here is a look at four penny stocks that may be worth tracking.
Halberd Corporation (OTC:HALB) is a research-based company involved in the discovery and development of treatments for a number of diseases. At this point, traumatic brain injury (TBI) is among the major healthcare challenges worldwide, and Halberd Corporation is one of the companies working on a solution for it.
On September 20, the company announced that it had gone into collaboration with Johnston, Iowa-based Athena GTX for the development of a solution for treating TBI and eventually submitting the same for government contracts. The basis of the collaboration would be the revolutionary proprietary nasal spray from Halberd Corporation for the mitigation of the effects of TBI.
TBI is a serious and life-altering condition that affects numerous people, including first responders, athletes, and military personnel. The company is involved in the development of the nasal spray at this point, and it is being tested by researchers at Mississippi State University.
The nasal spray had been synthesized in such a way as to limit the effects of the generation of inflammatory neurotransmitters and cytokines, which are brought about by TBI. The collaboration is geared towards the deployment of the unique product as a custom-formulated nasal spray that could be administered rapidly and easily in cases of emergency. That would make the nasal spray particularly useful for military war fighters and athletes in contact sports. The research data from the testing of the product on animals demonstrated the effectiveness of the approach.
Nate's Food Co. (OTC:NHMD) On September 22, the company announced that it had been successful in signing an agreement to complete the acquisition of JP Energy Group. The transaction was an accounting reverse merger.
In the news release, Nate's Food Co. noted that it would help the company make strategic progress into a new era of worldwide expansion, growth, change in control, and growth. It would also mark a key change in the leadership and management of the company, leading to the alignment of the company’s vision of getting into uncharted markets and pursuing operational clarity.
In order to facilitate the change, the director and chief financial officer of Nate's Food Co. stepped down from their positions as part of the deal. Nate Steck would continue with his position on the board in the transition period so as to ensure continuity. The company would also welcome new members to the board as a consequence of the merger.
Impact Fusion International Inc. (OTC:IFUS): The company is involved in marketing products in the health and wellness space in international markets. The mission of Impact Fusion International Inc. is to invent, develop, and eventually market its proprietary products globally for the health and wellness of animals and humans.
On August 1, its Chief Executive Officer, Marc Walther, joined The Stock Day Podcast for an interview. The CEO noted that every product which the company manufactured involved the deployment of NutriMastic. Walter went on to state that NutriMastic helped with digestion and went into all products. He also spoke about the current pipeline of products from Impact Fusion International, which is GMP certified.
He also noted that he had received positive feedback from ranchers, who make up one of the categories of customers. The products had helped reduce feed costs and also boosted nutrition. In the end, Walter asked all the listeners and the company’s shareholders to be abreast of the upcoming as well as current projects of Impact Fusion International.
GlobeStar Therapeutics Corporation (OTC: GSTC) The clinical-stage pharmaceutical firm is involved in the development of patented drug formulations meant for treating multiple sclerosis and other neurodegenerative conditions. On September 28, GlobeStar Therapeutics Corporation announced that it had inked a definitive agreement with SMI Healthcare Inc.
As per the provisions of the agreement, SMI Healthcare would oversee the initial clinical trial, intellectual property rights filings, manufacturing, regulatory filings, sales, and distribution of GlobeStar Therapeutics’ patented multiple sclerosis treatment in certain markets. The markets would include Southeast Asia, India, Africa, and the Middle East, but wouldn’t include Iraq and Israel. SMI Healthcare would also work with private aid and government organizations.
The President and Chief Executive Officer of the company, James C. Katzaroff, noted that SMI Healthcare, along with its affiliates, would collaborate closely with GlobeStar Therapeutics to advance the commercialization efforts of its product.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.